Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA‐HCM [PDF]
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseaseBackground Aficamten, a novel cardiac myosin inhibitor, reversibly reduces cardiac hypercontractility in obstructive hypertrophic cardiomyopathy. We present a prespecified analysis of the pharmacokinetics, pharmacodynamics, and safety of aficamten in ...
Caroline J. Coats +35 more
doaj +13 more sources
Cardiac myosin inhibitors: Efficacy, safety and future directions of aficamten in hypertrophic obstructive cardiomyopathy [PDF]
The Egyptian Heart JournalBackground Hypertrophic obstructive cardiomyopathy (HOCM) is a genetic disorder that affects the cardiac myocytes leading to asymmetric hypertrophy of the left ventricle and obstruction of the left ventricular outflow tract (LVOT) with possible risk of ...
Ikponmwosa Jude Ogieuhi +14 more
doaj +4 more sources
Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy [PDF]
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseaseBackground Cardiac myosin inhibitors were recently developed to address the underlying pathophysiology of hypertrophic cardiomyopathy and to improve symptoms and quality of life.
Bryton J. Davis +13 more
doaj +5 more sources
Safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of aficamten in healthy Chinese participants: a randomized, double-blind, placebo-controlled, phase 1 study [PDF]
Frontiers in Pharmacology, 2023 Objectives: Aficamten is a selective, small-molecule allosteric inhibitor of cardiac sarcomere being developed as a chronic oral treatment for patients with symptomatic obstructive hypertrophic cardiomyopathy.
Xue Zhao +17 more
doaj +3 more sources
Cardiac Myosin Inhibitors in the Treatment of Hypertrophic Cardiomyopathy: Clinical Trials and Future Challenges [PDF]
BiomoleculesHypertrophic cardiomyopathy (HCM) is a prevalent and often underdiagnosed genetic cardiac disorder characterized by left ventricular hypertrophy and, in many cases, dynamic left ventricular outflow tract obstruction (LVOTO).
Arnold Kukowka, Marek Droździk
doaj +2 more sources
Toward a Quantitative Understanding of Aficamten Clinical Pharmacology: Population Pharmacokinetic Modeling [PDF]
CPT: Pharmacometrics & Systems PharmacologyAficamten is a next‐in‐class, cardiac myosin inhibitor in development as a potential chronic oral treatment for patients with hypertrophic cardiomyopathy (HCM).
Donghong Xu +6 more
doaj +2 more sources
Comprehensive Review: Mavacamten and Aficamten in Hypertrophic Cardiomyopathy [PDF]
BiomedicinesHypertrophic cardiomyopathy (HCM) is the most common monogenic heart disease, with an estimated prevalence of 1:600 in the general population, and is associated with significant morbidity.
Helin Savsin, Tomasz Tokarek
doaj +2 more sources
Myosin Modulator Aficamten Inhibits Force by Altering Myosin’s Biochemical Activity Without Changing Thick Filament Structure [PDF]
JACC: Basic to Translational ScienceSummary: We investigated the effects of aficamten on cardiac muscle structure, biochemical activity, and contractile function. Aficamten does not structurally sequester myosin heads along the thick filament.
Saffie Mohran, PhD +17 more
doaj +2 more sources
Efficacy and safety of myosin inhibitors for symptomatic hypertrophic cardiomyopathy: systematic review and meta-analysis [PDF]
Archives of Medical Science: Atherosclerotic DiseasesIntroduction Hypertrophic cardiomyopathy (HCM) is a common genetic cardiac disorder associated with significant morbidity and mortality. Cardiac myosin inhibitors (MIs), including mavacamten and aficamten, offer a novel therapeutic approach for HCM ...
Mohammad Hazique +8 more
doaj +2 more sources
Clinical Evaluation of the Effect of Aficamten on QT/QTc Interval in Healthy Participants [PDF]
Clinical and Translational ScienceAficamten is a next‐in‐class, small‐molecule, cardiac myosin inhibitor in development for treating hypertrophic cardiomyopathy (HCM). This 2‐part study evaluated aficamten's impact on QTc interval in healthy participants.
Neha Maharao +9 more
doaj +2 more sources